1. Fast-Track Discovery of SARS-CoV-2-Neutralizing Antibodies from Human B Cells by Direct Functional Screening.
- Author
-
Hillenbrand, Matthias, Esslinger, Christoph, Seidenberg, Jemima, Weber, Marcel, Zingg, Andreas, Townsend, Catherine, Eicher, Barbara, Rutkauskaite, Justina, Riese, Peggy, Guzman, Carlos A., Fischer, Karsten, and Schmitt, Simone
- Subjects
B cells ,MONOCLONAL antibodies ,SARS-CoV-2 Omicron variant ,IMMUNOGLOBULINS ,SARS-CoV-2 ,VACCINE development - Abstract
As the COVID-19 pandemic revealed, rapid development of vaccines and therapeutic antibodies are crucial to guarantee a quick return to the status quo of society. In early 2020, we deployed our droplet microfluidic single-cell-based platform DROPZYLLA
® for the generation of cognate antibody repertoires of convalescent COVID-19 donors. Discovery of SARS-CoV-2-specific antibodies was performed upon display of antibodies on the surface of HEK293T cells by antigen-specific sorting using binding to the SARS-CoV-2 spike and absence of binding to huACE2 as the sort criteria. This efficiently yielded antibodies within 3–6 weeks, of which up to 100% were neutralizing. One of these, MTX-COVAB, displaying low picomolar neutralization IC50 of SARS-CoV-2 and with a neutralization potency on par with the Regeneron antibodies, was selected for GMP manufacturing and clinical development in June 2020. MTX-COVAB showed strong efficacy in vivo and neutralized all identified clinically relevant variants of SARS-CoV-2 at the time of its selection. MTX-COVAB completed GMP manufacturing by the end of 2020, but clinical development was stopped when the Omicron variant emerged, a variant that proved to be detrimental to all monoclonal antibodies already approved. The present study describes the capabilities of the DROPZYLLA® platform to identify antibodies of high virus-neutralizing capacity rapidly and directly. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF